Cardiovascular outcomes among patients with castration-resistant prostate cancer: A comparative safety study using US administrative claims data – PubMed
In the real world (outside of clinical trials), cardiovascular comorbidities really matter. Interesting article on the cardiovascular outcomes of patients treated with abiraterone and enzalutamide for men with mCRPC.